Zobrazeno 1 - 10
of 2 475
pro vyhledávání: '"TKIs resistance"'
Autor:
Diao Yunlian, Huang Shibo, Liu Fangpeng, Liao Shu, Guan Chenxi, Xiong Xiaojian, Zhang Ping, Li Junyao, Zhang Wei, Ying Ying
Publikováno v:
Acta Biochimica et Biophysica Sinica, Vol 56, Pp 1549-1560 (2024)
Acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) represents a primary cause of treatment failure in non-small cell lung cancer (NSCLC) patients. Chemokine (C-C motif) ligand 2 (CCL2) is recently found to play a pivotal role in deter
Externí odkaz:
https://doaj.org/article/2104750fcc1545be8f0a691301454a65
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Liu, Wen-Jing, Wang, Lin, Zhou, Feng-Mei, Liu, Shu-Wen, Wang, Wei, Zhao, Er-Jiang, Yao, Quan-Jun, Li, Wei, Zhao, Yan-Qiu, Shi, Zhi, Qiu, Jian-Ge, Jiang, Bing-Hua
Publikováno v:
In Drug Resistance Updates September 2023 70
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract The tumor microenvironment is a dynamic cellular milieu that interacts with cancer cells and promotes tumor progression and metastasis. However, the specific mechanisms by which the tumor microenvironment impacts cancer cells’ behaviors re
Externí odkaz:
https://doaj.org/article/670a69c5bac64b47ac386195cd00e2dd
Publikováno v:
Chinese Journal of Lung Cancer, Vol 25, Iss 8, Pp 601-608 (2022)
The follow-up treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation after drug resistance to EGFR-tyrosine kinase inhibitors (TKIs) have become a hotspot and difficulty at present
Externí odkaz:
https://doaj.org/article/07ce93ce70d54bcab9b5e595703d82da
Autor:
Zhenzhen Pan, Kai Wang, Xiniao Wang, Zhirong Jia, Yuqi Yang, Yalei Duan, Lianzhan Huang, Zhuo-Xun Wu, Jian-ye Zhang, Xuansheng Ding
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-17 (2022)
Abstract Background The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) brings remarkable benefits for the survival of patients with advanced NSCLC harboring EGFR mutations. Unfortunately, acquired resistance seems to b
Externí odkaz:
https://doaj.org/article/d60880850d5b4603bc028aaf3864412d
Autor:
Huibin Song, Dongcheng Liu, Lingwei Wang, Kaisheng Liu, Chen Chen, Le Wang, Yi Ren, Bing Ju, Fuhua Zhong, Xingyu Jiang, Guangsuo Wang, Zhe-Sheng Chen, Chang Zou
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-20 (2022)
Abstract Background Identification of potential novel targets for reversing resistance to Epidermal Growth Factor Receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) holds great promise for the treatment of relapsed lung adenocarcinoma (LUAD). In
Externí odkaz:
https://doaj.org/article/849d19aab0f44f8ab19ba4a76e68143c
Autor:
Pan, Zhenzhen1 (AUTHOR), Wang, Kai1 (AUTHOR), Wang, Xiniao1 (AUTHOR), Jia, Zhirong1 (AUTHOR), Yang, Yuqi2 (AUTHOR), Duan, Yalei1 (AUTHOR), Huang, Lianzhan1 (AUTHOR), Wu, Zhuo-Xun2 (AUTHOR), Zhang, Jian-ye3 (AUTHOR) jianyez@163.com, Ding, Xuansheng1 (AUTHOR) 1020030749@cpu.edu.cn
Publikováno v:
Molecular Cancer. 3/18/2022, Vol. 21 Issue 1, p1-17. 17p.
Autor:
Song, Huibin1,2,3 (AUTHOR), Liu, Dongcheng1,2 (AUTHOR), Wang, Lingwei3 (AUTHOR), Liu, Kaisheng1 (AUTHOR), Chen, Chen1 (AUTHOR), Wang, Le4 (AUTHOR), Ren, Yi1 (AUTHOR), Ju, Bing1 (AUTHOR), Zhong, Fuhua1 (AUTHOR), Jiang, Xingyu4 (AUTHOR), Wang, Guangsuo5 (AUTHOR) wgswy01@163.com, Chen, Zhe-Sheng6 (AUTHOR) chenz@stjohns.edu, Zou, Chang1,7,8 (AUTHOR) zou.chang@szhospital.com
Publikováno v:
Molecular Cancer. 2/10/2022, Vol. 21 Issue 1, p1-20. 20p.